AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22296762 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from intervention group participants
Number of subjects: 21
Study 18222552 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemanagement (HBT) program
Number of subjects: 460
Study 18222552 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) program
Number of subjects: 460
Study 16877007 — intervention group
Group type: EXPERIMENTAL
Intervention: SWS
Number of subjects: 0
Study 16877007 — intervention group
Group type: COMPARATOR
Intervention: REM sleep
Number of subjects: 0
Study 16877007 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness
Number of subjects: 0
Study 15101854 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid infusion (2000 ml)
Number of subjects: 34
Study 15101854 — intervention group
Group type: COMPARATOR
Intervention: Healthy control measurements by 10 EMTs
Number of subjects: 34
Study 12236394 — intervention group
Group type: EXPERIMENTAL
Intervention: CAHPS report along with standard enrollment materials
Number of subjects: 0
Study 12236394 — intervention group
Group type: COMPARATOR
Intervention: Standard enrollment materials (Control group)
Number of subjects: 0
Study 9635370 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) therapy
Number of subjects: 0
Study 9635370 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell factor (SCF) therapy
Number of subjects: 0
Study 9635370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (G‐CSF and SCF)
Number of subjects: 0
Study 7791682 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaptopril (Zorkaptil)
Number of subjects: 40
Study 7791682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2805603 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HPD) 2.0 g/kg ideal body weight
Number of subjects: 12
Study 2805603 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (NPD) 1 g/kg ideal body weight
Number of subjects: 12
Study 2805603 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD) 0.5 g/kg ideal body weight
Number of subjects: 12
Study 2805603 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HPD)
Number of subjects: 12
Study 2805603 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD)
Number of subjects: 12
Study 2805603 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NPD)
Number of subjects: 12
Study 809651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicor
Number of subjects: 24
Study 809651 — intervention group
Group type: COMPARATOR
Intervention: Card-Lamuran
Number of subjects: 24
Study 809651 — intervention group
Group type: COMPARATOR
Intervention: MF708d
Number of subjects: 24
Study 809651 — intervention group
Group type: COMPARATOR
Intervention: Lanitop
Number of subjects: 24
Study 31524836 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 626
Study 31524836 — intervention group
Group type: COMPARATOR
Intervention: Control (no prehospital plasma)
Number of subjects: 626
Study 29369454 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg twice daily)
Number of subjects: 270
Study 29369454 — intervention group
Group type: COMPARATOR
Intervention: 14-day PAM-B therapy (rabeprazole 20 mg, amoxicillin 1 g, metronidazole 750 mg, tripotassium dicitrato bismuthate 600 mg twice daily)
Number of subjects: 270
Study 29369454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 270
Study 27373556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen capsule
Number of subjects: 60
Study 27373556 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 60
Study 25467540 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural self-help treatment consisting of 14 modules over 8 weeks with weekly email feedback from a clinical psychologist.
Number of subjects: 0
Study 25467540 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving treatment after 8 weeks.
Number of subjects: 0
Study 22858557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a vaccination
Number of subjects: 35
Study 20678240 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 at baseline (T1) and after three months (T2)
Number of subjects: 239
Study 18312060 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg/day to 3000 mg/day
Number of subjects: 50
Study 18312060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15881484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of miconazole nitrate 1200 mg vaginal ovule
Number of subjects: 573
Study 15881484 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime administration of miconazole nitrate 1200 mg vaginal ovule
Number of subjects: 573
Study 15881484 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Daytime and Bedtime)
Number of subjects: 573
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg nefopam hydrochloride solution
Number of subjects: 24
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg nefopam hydrochloride
Number of subjects: 24
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of nefopam
Number of subjects: 24
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of nefopam
Number of subjects: 24
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral administration of nefopam
Number of subjects: 24
Study 12657915 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of parent and metabolite enantiomers
Number of subjects: 24
Study 10830223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine + Azathioprine (1 mg/kg/day)
Number of subjects: 116
Study 10830223 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine monotherapy
Number of subjects: 116
Study 8772679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (mean dose of 36 mg/d)
Number of subjects: 90
Study 8772679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8772679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin-treated smokers
Number of subjects: 90
Study 8772679 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated smokers
Number of subjects: 90
Study 8772679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (smokers)
Number of subjects: 90
Study 8772679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonsmokers)
Number of subjects: 90
Study 1602039 — intervention group
Group type: EXPERIMENTAL
Intervention: XYLIHEX
Number of subjects: 45
Study 1602039 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 45
Study 1602039 — intervention group
Group type: COMPARATOR
Intervention: NaF
Number of subjects: 45
Study 4092636 — intervention group
Group type: EXPERIMENTAL
Intervention: Early contact group (experimental)
Number of subjects: 22
Study 4092636 — intervention group
Group type: COMPARATOR
Intervention: Late contact group (control)
Number of subjects: 22
Study 30849721 — intervention group
Group type: COMPARATOR
Intervention: Inactive Control (IC) - benign video clip (nature scenes viewed while standing)
Number of subjects: 88
Study 30849721 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for children (TSST‐C)
Number of subjects: 88
Study 30626863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical isometric exercises in addition to standard physical and speech therapy for 12 weeks
Number of subjects: 70
Study 30626863 — intervention group
Group type: COMPARATOR
Intervention: Standard physical and speech therapy only
Number of subjects: 70
Study 26931055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg daily) plus NAC (2000 mg daily)
Number of subjects: 44
Study 26931055 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (200 mg daily) plus placebo
Number of subjects: 44
Study 24686045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg/2 mL with 50 mL IV normal saline
Number of subjects: 80
Study 24686045 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg in 50 mL normal saline
Number of subjects: 80
Study 24686045 — intervention group
Group type: COMPARATOR
Intervention: Perineural saline/2 mL with 50 mL normal saline
Number of subjects: 80
Study 24686045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg/2 mL
Number of subjects: 80
Study 24686045 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Number of subjects: 80
Study 24686045 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study 22271538 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and Attention Adaptation Training (MAAT)
Number of subjects: 40
Study 22271538 — intervention group
Group type: COMPARATOR
Intervention: Waitlist, no treatment control
Number of subjects: 40
Study 20359769 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 masks (1860 or 1860s or 1862; 3M, St Paul, MN, USA)
Number of subjects: 22
Study 20359769 — intervention group
Group type: EXPERIMENTAL
Intervention: Totobobo masks (Dream Lab One Pte Ltd, Singapore)
Number of subjects: 22
Study 20359769 — intervention group
Group type: COMPARATOR
Intervention: N95 masks
Number of subjects: 22
Study 20359769 — intervention group
Group type: COMPARATOR
Intervention: Totobobo masks
Number of subjects: 22
Study 18381573 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2 mg/d subcutaneously for 8 weeks
Number of subjects: 96
Study 18381573 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2 mg/d subcutaneously for 8 weeks + Testosterone (T) 250 mg/week intramuscularly for 5 weeks
Number of subjects: 96
Study 18381573 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) 250 mg/week intramuscularly for 5 weeks
Number of subjects: 96
Study 18381573 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 96
Study 15772568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 90 mg
Number of subjects: 118
Study 15772568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Number of subjects: 118
Study 15772568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 118
Study 15772568 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 118
Study 15772568 — intervention group
Group type: EXPERIMENTAL
Intervention: All ospemifene groups
Number of subjects: 118
Study 15772568 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 118
Study 12438990 — intervention group
Group type: EXPERIMENTAL
Intervention: InFUSE Bone Graft with threaded cortical allograft dowels
Number of subjects: 46
Study 12438990 — intervention group
Group type: COMPARATOR
Intervention: Control group with threaded allograft dowels and autogenous iliac crest bone graft
Number of subjects: 46
Study 10343132 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 46
Study 10343132 — intervention group
Group type: COMPARATOR
Intervention: Exposure to H. pylori
Number of subjects: 46
Study 7860757 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 0.5 mU/kg-1 per min-1
Number of subjects: 0
Study 7860757 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 1.0 mU/kg-1 per min-1
Number of subjects: 0
Study 7860757 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (both low and high)
Number of subjects: 0
Study 7860757 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 0
Study 2006767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole thallium 201 tomography
Number of subjects: 45
Study 2006767 — intervention group
Group type: COMPARATOR
Intervention: Left ventriculography
Number of subjects: 45
Study 6812687 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarred kidneys (n=18)
Number of subjects: 48
Study 6812687 — intervention group
Group type: COMPARATOR
Intervention: Unscarred kidneys (n=30)
Number of subjects: 48
Study 31138256 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP‐KOA (internet-based exercise program for 3 months)
Number of subjects: 345
Study 31138256 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP‐KOA (bi-weekly physical activity coaching calls for 3 months)
Number of subjects: 345
Study 31138256 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP‐KOA (in-person PT visits if needed)
Number of subjects: 345
Study 31138256 — intervention group
Group type: COMPARATOR
Intervention: Arthritis Education (AE) Control group
Number of subjects: 345
Study 29262836 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated postoperative radiotherapy (7 fractions per week, 2 Gy fractions)
Number of subjects: 0
Study 29262836 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative radiotherapy (5 fractions per week, 2 Gy fractions)
Number of subjects: 0
Study 29262836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 0
Study 24978062 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure with Sea-Band
Number of subjects: 95
Study 24978062 — intervention group
Group type: COMPARATOR
Intervention: Sham group (placebo)
Number of subjects: 95
Study 24911034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction (ONPS)
Number of subjects: 170
Study 24911034 — intervention group
Group type: COMPARATOR
Intervention: No suction
Number of subjects: 170
Study 22935569 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 452
Study 22935569 — intervention group
Group type: COMPARATOR
Intervention: IABP
Number of subjects: 452
Study 19684522 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient oral ofloxacin 7.5 mg/kg 12 hourly and amoxycillin‐clavulanate 12.5 mg/kg 8 hourly
Number of subjects: 88
Study 19684522 — intervention group
Group type: COMPARATOR
Intervention: Outpatient intravenous (IV) ceftriaxone 75 mg/kg and amikacin 15 mg/kg once daily
Number of subjects: 88
Study 19684522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and IV arms
Number of subjects: 88
Study 17471546 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 intravenous cyclophosphamide pulses
Number of subjects: 48
Study 17471546 — intervention group
Group type: COMPARATOR
Intervention: 6 intravenous cyclophosphamide pulses
Number of subjects: 48
Study 15040503 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 30 mg twice daily
Number of subjects: 44
Study 15040503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg plus medroxyprogesterone 30 mg twice daily
Number of subjects: 44
Study 15040503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15040503 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide 250 mg plus placebo twice daily
Number of subjects: 44
Study 15040503 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Number of subjects: 44
Study 11958306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (NP temperature maintained at 28.0-28.5 degrees C, arterial blood temperature lowered to 25.0 degrees C, re-warmed to 38.0 degrees C)
Number of subjects: 80
Study 11958306 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (NP temperature maintained at 36.5-37.0 degrees C, arterial blood temperature raised to a maximum of 37.0 degrees C)
Number of subjects: 80
Study 9652236 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage pulsed current (HVPC) in an energized wrist splint
Number of subjects: 120
Study 9652236 — intervention group
Group type: COMPARATOR
Intervention: Non-energized unit in an identical splint (Control)
Number of subjects: 120
Study 10335187 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient goal setting and interdisciplinary collaboration and support
Number of subjects: 0
Study 1852905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 15
Study 1852905 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 15
Study 6686456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 10
Study 6686456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31949295 — intervention group
Group type: EXPERIMENTAL
Intervention: WW with diabetes counseling
Number of subjects: 563
Study 31949295 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 563
Study 31949295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 563
Study 31115552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical supplements (NS)
Number of subjects: 47
Study 31115552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 30059775 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (Group 1)
Number of subjects: 34
Study 30059775 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Group 2)
Number of subjects: 34
Study 26808861 — intervention group
Group type: EXPERIMENTAL
Intervention: Long warm-up (20 minutes: LWup)
Number of subjects: 10
Study 26808861 — intervention group
Group type: COMPARATOR
Intervention: Short warm-up (10 minutes: SWup)
Number of subjects: 10
Study 24615075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise + mosapride
Number of subjects: 80
Study 24615075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise
Number of subjects: 80
Study 24615075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 80
Study 24615075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 22460927 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIDGES peer‐led education intervention
Number of subjects: 428
Study 22460927 — intervention group
Group type: COMPARATOR
Intervention: services as usual wait list (control condition)
Number of subjects: 428
Study 20051371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO (500 mg/m2/day)
Number of subjects: 291
Study 20051371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 16569396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance group
Number of subjects: 219
Study 16569396 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group
Number of subjects: 219
Study 16569396 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous coping group
Number of subjects: 219
Study 16340560 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy followed by early laparoscopic cholecystectomy (PCLC)
Number of subjects: 61
Study 16340560 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment followed by delayed laparoscopic cholecystectomy (DLC)
Number of subjects: 61
Study 11882102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 495
Study 11882102 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 495
Study 9296896 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge (n = 11)
Number of subjects: 24
Study 9296896 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen antigen challenge (n = 8)
Number of subjects: 24
Study 9296896 — intervention group
Group type: COMPARATOR
Intervention: PBS control (n = 5)
Number of subjects: 24
Study 8320928 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide membrane
Number of subjects: 10
Study 8320928 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylonitrile membrane
Number of subjects: 10
Study 3636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin (ticarcillin 3 g plus potassium clavulanate 200 mg)
Number of subjects: 78
Study 3636340 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (125-200 mg/kg per day)
Number of subjects: 78
Study 3636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin and Piperacillin (both groups)
Number of subjects: 78
Study 3636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin
Number of subjects: 78
Study 3636340 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 78
Study 29229498 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily, modified-release hydrocortisone
Number of subjects: 89
Study 29229498 — intervention group
Group type: COMPARATOR
Intervention: Standard glucocorticoid therapy
Number of subjects: 89
Study 25829064 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior 120° fundoplication (APF)
Number of subjects: 72
Study 25829064 — intervention group
Group type: COMPARATOR
Intervention: Total fundoplication (Nissen)
Number of subjects: 72
Study 23818505 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about personal life goals
Number of subjects: 68
Study 23818505 — intervention group
Group type: COMPARATOR
Intervention: Control topic writing
Number of subjects: 68
Study 22276959 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Burden Index (DBI) low category (n=260)
Number of subjects: 602
Study 22276959 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Burden Index (DBI) high category (n=153)
Number of subjects: 602
Study 22276959 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to anticholinergic medication (33.6%) and sedative medications (41.9%)
Number of subjects: 602
Study 22276959 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality after follow-up (774-1269 days)
Number of subjects: 602
Study 20176120 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM-only daytime nap (n=14)
Number of subjects: 31
Study 20176120 — intervention group
Group type: COMPARATOR
Intervention: Equivalent waking period (n=17)
Number of subjects: 31
Study 19011281 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) 6.0 g/day
Number of subjects: 48
Study 19011281 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.8 g/day
Number of subjects: 48
Study 19011281 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 2.9 g/day
Number of subjects: 48